Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) for the reporting period ending November 21, 2007, covering events occurring on November 19 and 20, 2007. The filing details the entry into material definitive agreements regarding the potential sale of equity securities to two Korean corporations.
Key Financial Metrics and Transaction Terms
The filing outlines two proposed Securities Purchase Agreements with the following terms:
- KT&G Corporation Agreement (Nov 19, 2007):
- Aggregate Cash Consideration: $3,000,001.20
- Securities: 2,142,858 shares of Common Stock and a Warrant for 428,572 shares.
- Warrant Exercise Price: $1.80 per share.
- Rexgene Biotech Co., Ltd. Agreement (Nov 20, 2007):
- Aggregate Cash Consideration: $1,000,000.40
- Securities: 714,286 shares of Common Stock and a Warrant for 142,857 shares.
- Warrant Exercise Price: $1.80 per share.
- Total Potential Proceeds: Approximately $4,000,001.60 (subject to conditions).
Financial Metrics Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Conditions Precedent
The transactions are subject to significant conditions that have not yet been met:
- KT&G Condition: The obligation to purchase is contingent upon Rexahn receiving binding commitments from third parties to purchase an additional $5,000,000 of Common Stock and warrants on terms no less favorable. As of the report date, these commitments have not been received.
- Rexgene Condition: The obligation to purchase is contingent upon the prior or contemporaneous closing of the KT&G transaction.
- Termination Date: The KT&G agreement will terminate if closing does not occur by December 31, 2007.
Outlook, Risks, and Unusual Items
Anti-Dilution Provisions (Full Ratchet):
- Stock: If Rexahn issues stock below $1.40 per share within two years, investors receive additional shares to adjust their effective purchase price to the lowest new price.
- Warrants: If Rexahn issues stock below $1.80 per share, the warrant exercise price is reduced to the lowest new price.
Listing Obligation and Penalties:
- Rexahn must use commercially reasonable efforts to list Common Stock on the American Stock Exchange (AMEX) within three years.
- Liquidated Damages: If a resale registration statement is not filed within 60 days of AMEX listing, Rexahn must pay monthly damages equal to 2% of the investment amount.
- Interest Penalty: Unpaid damages accrue interest at 18% per annum.
Risks: There is no assurance that the required third-party commitments will be received or that the transactions will close.
Investor Verification Checklist
- Verify whether the required $5,000,000 in third-party commitments were secured before the December 31, 2007 deadline.
- Confirm if the transactions with KT&G and Rexgene ultimately closed.
- Monitor the company's progress toward listing on the AMEX to avoid liquidated damages.
- Review future capital raises to assess the impact of the full ratchet anti-dilution provisions on existing shareholders.
- Check subsequent filings for any updates on the company's liquidity and cash position, as this filing does not provide current financial statements.